Trial Profile

A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vactosertib (Primary)
Indications Anaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
Focus Adverse reactions; Therapeutic Use

11 Nov 2024 According to ClinicalTrials.gov: US National Institutes of Health, endpoints replace by 8 new safety and efficacy endpoints.
11 Nov 2024 Status changed from recruiting to discontinued.
16 Nov 2023 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com